piTracer - Automatic reconstruction of molecular cascades for the identification of synergistic drug targets

Cancer cells frequently undergo metabolic reprogramming as a mechanism of resistance against chemotherapeutic drugs. Metabolomic profiling provides a direct readout of metabolic changes and can thus be used to identify these tumor escape mechanisms. Here, we introduce piTracer, a computational tool that uses multi-scale molecular networks to identify potential combination therapies from pre- and post-treatment metabolomics data. We first demonstrate piTracer’s core ability to reconstruct cellular cascades by inspecting well-characterized molecular pathways and previously studied associations between genetic variants and metabolite levels. We then apply a new gene ranking algorithm on differential metabolomic profiles from human breast cancer cells after glutaminase inhibition. Four of the automatically identified gene targets were experimentally tested by simultaneous inhibition of the respective targets and glutaminase. Of these combination treatments, two were be confirmed to induce synthetic lethality in the cell line. In summary, piTracer integrates the molecular monitoring of escape mechanisms into comprehensive pathway networks to accelerate drug target identification. The tool is open source and can be accessed at https://github.com/krumsieklab/pitracer.

[1]  F. Matsuda,et al.  Metabolomics-based phenotypic screens for evaluation of drug synergy via direct-infusion mass spectrometry , 2022, iScience.

[2]  I. Enyedy,et al.  Discovery of Phospholipase D Inhibitors with Improved Drug-like Properties and Central Nervous System Penetrance. , 2022, ACS medicinal chemistry letters.

[3]  Gabor T. Marth,et al.  A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology , 2022, Nature Cancer.

[4]  D. Hanahan Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[5]  E. Voest,et al.  Tumor organoids: Opportunities and challenges to guide precision medicine. , 2021, Cancer cell.

[6]  E. Ruppin,et al.  Synthetic lethality-mediated precision oncology via the tumor transcriptome , 2021, Cell.

[7]  P. Paoli,et al.  Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids. , 2021, Trends in cancer.

[8]  Benjamin A. Shoemaker,et al.  PubChem in 2021: new data content and improved web interfaces , 2020, Nucleic Acids Res..

[9]  Aziz Mithani,et al.  MAPPS: A Web-Based Tool for Metabolic Pathway Prediction and Network Analysis in the Postgenomic Era. , 2020, ACS synthetic biology.

[10]  James H. Joly,et al.  A synthetic lethal drug combination mimics glucose deprivation–induced cancer cell death in the presence of glucose , 2019, The Journal of Biological Chemistry.

[11]  A. Ashworth,et al.  Synthetic lethality as an engine for cancer drug target discovery , 2019, Nature Reviews Drug Discovery.

[12]  D. Wishart Metabolomics for Investigating Physiological and Pathophysiological Processes. , 2019, Physiological reviews.

[13]  Xiaozhuo Chen,et al.  Drug resistance and combating drug resistance in cancer , 2019, Cancer drug resistance.

[14]  Min Su,et al.  The roles of glucose metabolic reprogramming in chemo- and radio-resistance , 2019, Journal of experimental & clinical cancer research : CR.

[15]  Fabian J Theis,et al.  Dynamic modelling of an ACADS genotype in fatty acid oxidation – Application of cellular models for the analysis of common genetic variants , 2019, PloS one.

[16]  A. Silber,et al.  Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition–resistant triple-negative breast cancer cells , 2019, The Journal of Biological Chemistry.

[17]  Mathias Uhlen,et al.  Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning , 2019, EBioMedicine.

[18]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[19]  Paul Denny,et al.  Genenames.org: the HGNC and VGNC resources in 2019 , 2018, Nucleic Acids Res..

[20]  B. Goh,et al.  Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance , 2018, Redox biology.

[21]  O. Elemento,et al.  Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis , 2018, bioRxiv.

[22]  E. Ruppin,et al.  Harnessing synthetic lethality to predict the response to cancer treatment , 2018, Nature Communications.

[23]  Piotr Gawron,et al.  The Virtual Metabolic Human database: integrating human and gut microbiome metabolism with nutrition and disease , 2018, bioRxiv.

[24]  Gary Siuzdak,et al.  Metabolomics activity screening for identifying metabolites that modulate phenotype , 2018, Nature Biotechnology.

[25]  P. Oefner,et al.  Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells. , 2018, Cancer research.

[26]  J. Phillip,et al.  Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway , 2018, EBioMedicine.

[27]  J. Vockley,et al.  Inborn Errors of Metabolism with Myopathy: Defects of Fatty Acid Oxidation and the Carnitine Shuttle System. , 2017, Pediatric clinics of North America.

[28]  David S. Wishart,et al.  HMDB 4.0: the human metabolome database for 2018 , 2017, Nucleic Acids Res..

[29]  Daniel C. Zielinski,et al.  Recon3D enables a three-dimensional view of gene variation in human metabolism , 2018 .

[30]  S. Indraccolo,et al.  Linking metabolic reprogramming to therapy resistance in cancer. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[31]  Abhijeet R. Sonawane,et al.  Understanding Tissue-Specific Gene Regulation , 2017, bioRxiv.

[32]  Katharina Anna Zweig,et al.  Clustering of Paths in Complex Networks , 2016, COMPLEX NETWORKS.

[33]  Julio Saez-Rodriguez,et al.  OmniPath: guidelines and gateway for literature-curated signaling pathway resources , 2016, Nature Methods.

[34]  Christoph Steinbeck,et al.  Reaction Decoder Tool (RDT): extracting features from chemical reactions , 2016, Bioinform..

[35]  K. V. van Dijk,et al.  Reanalysis of mGWAS results and in vitro validation show that lactate dehydrogenase interacts with branched-chain amino acid metabolism , 2015, European Journal of Human Genetics.

[36]  K. Suhre,et al.  Metabolic switch during adipogenesis: From branched chain amino acid catabolism to lipid synthesis. , 2016, Archives of biochemistry and biophysics.

[37]  G. J. Yoshida Metabolic reprogramming: the emerging concept and associated therapeutic strategies , 2015, Journal of experimental & clinical cancer research : CR.

[38]  A. Vazquez,et al.  Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis , 2015, Nature Cell Biology.

[39]  G. Kempermann Faculty Opinions recommendation of Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. , 2015 .

[40]  Eytan Ruppin,et al.  Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality , 2014, Cell.

[41]  John P. Overington,et al.  An atlas of genetic influences on human blood metabolites , 2014, Nature Genetics.

[42]  Mong-Hong Lee,et al.  Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies , 2014, Cancer biology & medicine.

[43]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[44]  Ming-Huei Chen,et al.  A genome-wide association study of the human metabolome in a community-based cohort. , 2013, Cell metabolism.

[45]  C. Huttenhower,et al.  Passing Messages between Biological Networks to Refine Predicted Interactions , 2013, PloS one.

[46]  Ralf Herwig,et al.  The ConsensusPathDB interaction database: 2013 update , 2012, Nucleic Acids Res..

[47]  E. Ruppin,et al.  Predicting selective drug targets in cancer through metabolic networks , 2011, Molecular systems biology.

[48]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[49]  R. Wanders,et al.  A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation , 2010, Journal of Inherited Metabolic Disease.

[50]  Christian Gieger,et al.  A genome-wide perspective of genetic variation in human metabolism , 2010, Nature Genetics.

[51]  Bin Zhang,et al.  Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R , 2008, Bioinform..

[52]  J. Y. Yen,et al.  Finding the K Shortest Loopless Paths in a Network , 2007 .

[53]  Lei Sun,et al.  Crystal structure of the pyridoxal‐5′‐phosphate‐dependent serine dehydratase from human liver , 2005, Protein science : a publication of the Protein Society.

[54]  K. Bohren,et al.  Characterization of the human aldehyde reductase gene and promoter. , 1999, Genomics.

[55]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[56]  S. Yorifuji [Carnitine/acylcarnitine translocase deficiency]. , 1998, Ryoikibetsu shokogun shirizu.

[57]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.